MGX Live signals | Maximize Profits with Getagraph.com

SELL 119461 min ago

@ $12.23

Issued: 14 Feb 2024 @ 13:22

Return: -48.57%

Previous signal: Feb 13 - 14:08

Previous signal: Buy

Return: 5.43 %

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 13:08):

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States...

Stats
Today's Volume	126 818
Average Volume	220 168
Market Cap	235.70M
Next earnings date	( $0 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0400 (0.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Novo Holdings A/s	Sell	147 415	SERIES B PREFERRED STOCK
2024-02-08	Novo Holdings A/s	Sell	691 760	SERIES B-1 PREFERRED STOCK
2024-02-08	Noonberg Sarah B.	Sell	0	Common Stock
2024-02-08	Borges Luis	Buy	0

INSIDER POWER
-100.00
Last 3 transactions
Buy: 0 \| Sell: 839 175

Volume Correlation

Long: -0.08 (neutral)

Short: 0.56 (weak)

Signal:(45.358) Neutral

Metagenomi, Inc. Common Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Metagenomi, Inc. Common Correlation - Currency/Commodity

-0.42
( neutral )

-0.14
( neutral )

0.00
( neutral )

-0.68
( moderate negative )

0.14
( neutral )

0.55
( weak )

Financial Reports:

No articles found.

Metagenomi, Inc. Common

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.